Drinking extra water or other non-caloric beverages for promoting weight loss or preventing weight gain by Burls, A. et al.
Burls, A., Price, A.I., Cabello, J.B. & Roberts, N.W. (2016). Drinking extra water or other non-caloric 
beverages for promoting weight loss or preventing weight gain. Cochrane Database of Systematic 
Reviews(5), doi: 10.1002/14651858.CD012211 
City Research Online
Original citation: Burls, A., Price, A.I., Cabello, J.B. & Roberts, N.W. (2016). Drinking extra water 
or other non-caloric beverages for promoting weight loss or preventing weight gain. Cochrane 
Database of Systematic Reviews(5), doi: 10.1002/14651858.CD012211 
Permanent City Research Online URL: http://openaccess.city.ac.uk/17364/
 
Copyright & reuse
City University London has developed City Research Online so that its users may access the 
research outputs of City University London's staff. Copyright © and Moral Rights for this paper are 
retained by the individual author(s) and/ or other copyright holders.  All material in City Research 
Online is checked for eligibility for copyright before being made available in the live archive. URLs 
from City Research Online may be freely distributed and linked to from other web pages. 
Versions of research
The version in City Research Online may differ from the final published version. Users are advised 
to check the Permanent City Research Online URL above for the status of the paper.
Enquiries
If you have any enquiries about any aspect of City Research Online, or if you wish to make contact 
with the author(s) of this paper, please email the team at publications@city.ac.uk.
Cochrane Database of Systematic Reviews
Drinking extra water or other non-caloric beverages for
promoting weight loss or preventing weight gain (Protocol)
Burls A, Price AI, Cabello JB, Roberts NW
Burls A, Price AI, Cabello JB, Roberts NW.
Drinking extra water or other non-caloric beverages for promoting weight loss or preventing weight gain.
Cochrane Database of Systematic Reviews 2016, Issue 5. Art. No.: CD012211.
DOI: 10.1002/14651858.CD012211.
www.cochranelibrary.com
Drinking extra water or other non-caloric beverages for promotingweight loss or preventing weight gain (Protocol)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
T A B L E O F C O N T E N T S
1HEADER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1ABSTRACT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1BACKGROUND . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3OBJECTIVES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3METHODS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
10REFERENCES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
13APPENDICES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
18CONTRIBUTIONS OF AUTHORS . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
18DECLARATIONS OF INTEREST . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
18NOTES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
iDrinking extra water or other non-caloric beverages for promoting weight loss or preventing weight gain (Protocol)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
[Intervention Protocol]
Drinking extra water or other non-caloric beverages for
promoting weight loss or preventing weight gain
Amanda Burls1, Amy I Price2, Juan B Cabello3, Nia W Roberts4
1School of Health Sciences, City University London, London, UK. 2Research and Development, Empower 2 Go, Edmonton, UK.
3Department of Cardiology & CASP Spain, Hospital General Universitario de Alicante, Alicante, Spain. 4Bodleian Health Care
Libraries, University of Oxford, Oxford, UK
Contact address: Amanda Burls, School of Health Sciences, City University London, Myddleton Street, London, EC1V 0HB, UK.
Amanda.Burls.1@city.ac.uk.
Editorial group: Cochrane Metabolic and Endocrine Disorders Group.
Publication status and date: New, published in Issue 5, 2016.
Citation: Burls A, Price AI, Cabello JB, Roberts NW. Drinking extra water or other non-caloric beverages for promoting
weight loss or preventing weight gain. Cochrane Database of Systematic Reviews 2016, Issue 5. Art. No.: CD012211. DOI:
10.1002/14651858.CD012211.
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
A B S T R A C T
This is the protocol for a review and there is no abstract. The objectives are as follows:
To assess the effects of drinking extra water or other non-caloric beverages for promoting weight loss or preventing weight gain.
B A C K G R O U N D
Obesity is increasingly common and has adverse effects on mor-
bidity and mortality. Many people want to lose weight yet struggle
to do so. In addition, public health research shows limited long-
term success rates for dieting interventions (Chan 2010; Walls
2011). Observational and non-randomised intervention studies
across multiple age groups suggest that there is an inverse corre-
lation between fluid intake and weight, and as a result advice to
drink extra water has been recommended as an aid to weight loss
(Daniels 2011; Pan 2013; Popkin 2005; Stookey 2008).
The question of extra water intake is important for multiple rea-
sons. When medications are used to reduce weight gain, serious
side effects, such as liver, kidney and even heart problems can oc-
cur (Johansson 2009). Bariatric surgery is considered an effective
treatment for obesity, however serious adverse effects may occur
and operated people remain at risk for adverse events for at least
one year post-intervention and at slightly elevated risk for five
years (Bolen 2012; Khwaja 2010). Serious adverse outcomes may
include peritonitis, scarring, ulcers, haemorrhage, gangrene and
aspiration or bacterial pneumonia (Bolen 2012; Gagnon 2012).
Dieters may enjoy an initial weight loss through diet and medi-
cation, however sustained weight loss is less frequent and this can
reinforce a failure cycle where diets can do more harm than good
(Green 2009; Haslam 2006; Walls 2011).
Description of the condition
Being obese or overweight puts physical health at risk. The World
Health Organization (WHO) (WHO 2011) and NHSIC 2011
advise that excess body weight is a medical condition that may
compromise health, quality of life and life expectancy. An increase
in body fat normally requires energy intake to exceed energy ex-
penditure. This means we must consume more calories than are
burned in metabolic and physical activity or the balance of unused
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energy will be stored as fat. NICE 2006 uses body mass index
(BMI), calculated by dividing a person’s weight in kilograms by
the square of their height in metres, as a measure for the classifi-
cation of overweight or obesity.
Excess weight, often defined as a BMI of 25 or over, is a recognised
risk factor for health and is correlated with increased morbidity
and mortality. International obesity rates have doubled since 1980
and it is estimated that 1.4 billion adults are overweight or obese
(defined as a BMI of 30 or over) (WHO 2011). Excess weight
is defined as a level of adiposity that compromises health, quality
of life and life expectancy. Overweight and obesity are furtheron
categorised as follows:
• Overweight: BMI 25 to 29.9 kg/m2
• Obesity class I: BMI 30 to 34.9 kg/m2
• Obesity class II: BMI 35 to 39.9 kg/m2
• Obesity class III: BMI ≥ 40.0 kg/m2
The WHO reports that international obesity rates have doubled
since 1980. WHO estimates that 1.4 billion adults aged 20 and
older are overweight; 200 millionmen and 300 million women are
obese (BMI ≥30); and 40 million children under five years of age
are overweight (WHO 2011). Obesity puts individuals at risk for
cardiovascular disease, diabetes, organ failure, sleep apnoea, and
some cancers (National Cancer Institute 2012;NICE2006).Mus-
culoskeletal disorders can be aggravated by excessive weight gain
(Reynolds 2009). Obese individuals may endure social isolation
and depression (Haslam 2006). People on certain medications can
be less sensitive to cues of hunger, thirst and satiety (Kovacs 1992).
Overweight and obesity describes the accumulation of body fat
to the extent that impairs health although the BMI at which fat
accumulation is considered unhealthy is controversial. Flegal and
colleagues conducted a systematic review, which found overweight
but not obese persons lived longer than ideal or underweight in-
dividuals (Flegal 2013). Moreover, there is an apparent lack of
long-term success for popular diets, and an accumulation of extra
weight within two years for many dieters, post-diet is reported
(Chan 2010).
Description of the intervention
The intervention consists of increased water consumption, ad-
vice or encouragement to increase water consumption or increased
availability of or access to water (e.g. provision of water fountains
or access to bottled water). Controls will consist of usual practice
defined as unchanged water consumption or availability or advice,
or encouragement of consumption of a lower volume of water than
in the intervention group. We will not restrict this review in terms
of qualifications for personnel who administered or assisted with
the intervention and in addition we will accept patient-reported
outcomes. We anticipate that researchers, physicians, nutrition or
diet professionals, teachers, physical activity professionals, health
promotion agencies, health department staff, instructors or other
institution staff could be promoting this intervention and all will
be included.
Adverse effects of the intervention
Drinking large volumes of water can cause frequent or nocturnal
micturition and, rarely, can lead to water toxicity and death, espe-
cially in vulnerable individuals with, for example, renal or cardiac
impairment (Kovacs 1992).
How the intervention might work
Observational studies show an inverse correlation between fluid
intake and weight (Pan 2013).In a non-randomised controlled
interventional trial, where drinking water and education about
nutritionwas provided to 2nd to 3rd graders in selected schools and
not to control schools, water consumption was higher and weight
was lower in children given water and nutritional education than
in those who were not (Muckelbauer 2009; Muckelbauer 2011).
Drinking water could affect weight by reducing caloric intake
or increasing energy use. Mechanisms by which it could reduce
caloric intake include: people drinking water will be well hydrated
andmay be less inclined to consume caloric beverages; people who
confuse thirst signals with hunger (Mattes 2010) are less likely to
feel hungry; drinking water may help people to feel fuller or more
satiated at meal times (Popkin 2005). Other recommendations
suggest a pre-load of water before meals can reduce hunger and
increase satiety (Pan 2013). A systematic review and meta-analy-
sis found that preloading with liquids, semi-solids or solids 30 to
120 minutes before a meal resulted in fewer calories eaten during
the meal. The authors report that preloads used with older obese
individuals may result in greater energy reduction, however they
were unable to confirm this finding without individual patient
data (Almiron-Roig 2013).
Water consumption may have direct effects on hunger hormones
(Clark 2013). These are defined as ghrelin, leptin, insulin, chole-
cystokinin (CCK) and glucagon-like peptide-1 (GPL-1). The ef-
fects are described in Mattes 2010. Ghrelin increases appetite by
signalling hunger to the brain and is released primarily in the stom-
ach. Leptin is an appetite suppressant made by fat cells. Insulin
is made in the pancreas to enable the body to metabolise sugar
(glucose) from carbohydrates and when there is an imbalance this
can affect hunger levels. Cholecystokinin stimulates the digestion
of fat and protein. GLP-1 is produced in the gut and released
in response to food where it stimulates insulin secretion and in-
hibits glucagon secretion and this contributes to feelings of satiety
(Mattes 2010). Drinking extra water may rate limit the biochem-
ical steps needed to metabolise fat because the glycaemic and in-
sulin index of water is zero. This simplifies the fat breakdown of
free fatty acids and the transport of these free fatty acids into the
mitochondria where fat is oxidised. Drinking water rather than
orange juice was noted to increase fat oxidation in normal weight
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individuals following a breakfast when tested on two consecutive
days, even when they consumed more calories than they expended
and engaged in no other intervention to reduce the calorie balance
(Stookey 2012). Two days is not enough time to conclude that
extra water intake is effective as a weight loss tool, however it is a
promising observation.
In comparison with those who drank sweetened beverages and
semi-skimmed milk, those who drank water and artificially sweet-
ened beverages had lower ectopic fat (fat storage in non-adi-
pose tissue) in the liver and muscle over a six-month period
(Maersk 2012). The Choose Healthy Options Consciously Every-
day (CHOICE) trial looked at multiple interventions and found
that substituting water for high caloric beverages was a support-
ive compensatory strategy for weight loss (Piernas 2013). Mid-
dle-aged water drinkers were reported to have a 9% (194 kcal/d)
lower caloric intake thanmiddle-aged non-water drinkers (Dennis
2010). This population is also more likely to be on prescription
medications that could make them less sensitive to cues of hunger,
thirst and satiety (Daniels 2011; Kovacs 1992). Mechanisms by
which drinking water could increase caloric expenditure include
a direct effect on metabolic rate (Shaw 2009), as even a 1% de-
hydration can cause a drop in metabolic rate (Thornton 2010);
or it could simply be that people who are well hydrated are more
disposed to increased physical activity.
Why it is important to do this review
Obesity in the United Kingdom (UK) population continues to
climb, with the Foresight report projecting obesity in over half of
UK adults by 2050 (Butland 2007). The National Health Service
(NHS) projects obesity-related medical costs will double by 2050
to £10 billion per year. The additional and indirect cost to soci-
ety is estimated to reach £49.9 billion per year when calculated
at 2015 prices (McPherson 2007). The global cost of obesity in
direct and indirect costs is staggering and is estimated to be $2
trillion a year according to the 2014 McKinsey report; it will ex-
ceed the combined global costs of war, armed violence, and terror-
ism (Dobbs 2014). These figures, and the reality that no nation
has successfully reduced population obesity,makes sustainable and
successful interventions a public health priority (Lobstein 2007).
Despite the large number of people trying to prevent weight gain,
they struggle to do so - as can be observed in the increased global
prevalence of obesity (Pietiläinen 2012). A qualitative review from
Stookey 2016 reports that extra water intake was associated with
a short-term decrease in energy intake, an increase in energy effi-
ciency and increased fat absorption. The trend was sustained over
time resulting in better weight management for some populations,
given specific conditions. Further research is needed to confirm
the observed associations and to define and optimise the interven-
tional use of drinking extra water for weightmanagement. If water
can reduce adiposity, it is a simple, non-invasive and inexpensive
alternative or addition to diets, pharmaceuticals, bariatric surgery,
and physical training.
Competing interests in the diet and bottled water industry could
make people vulnerable to marketing ploys by overestimating the
success of dieting interventions and underestimating the danger
of extreme water intake (Valtin 2002). It is prudent to establish
whether additional water intake has an effect on weight, not only
to know if we should advise people to drink water to help with
weight control, but also because water has been used as a control
intervention in diet trials (Poppitt 2011; Silver 2011). If water is
effective, this makes the interpretation of such trials more chal-
lenging.Promoting water for weight reduction when it is ineffec-
tive could increase resource costs by causing a delay before people
who are obese seek effective care, and could endanger vulnerable
people who over-consume water (Kovacs 1992; Upadhyay 2009).
O B J E C T I V E S
To assess the effects of drinking extra water or other non-caloric
beverages for promoting weight loss or preventing weight gain.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will include randomised controlled clinical trials (RCTs).
Types of participants
Participants of all ages, any weight, healthy or with comorbidity,
with the exception of those that meet the exclusion criterion of
increased fluids for other conditions, or indications such as pre-
venting urinary tract infections, or bladder cancer.
Types of interventions
Interventions
(a) Intake of additional drinking water (or non-caloric beverages)
to that consumed ad libitum.
(b) Intake of additional drinking water (or non-caloric beverages)
to that consumed ad libitum at specific times, such as in themorn-
ing or before meals.
(c) Provision of, or improved access to water (or non-caloric bev-
erages) for participants.
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Comparators
• Normal fluid consumption, or drinking 120 ml or less of
extra water daily, or placebo intervention not related to weight
control for comparison with (a).
• Normal fluid consumption, or drinking 120 ml or less of
extra water daily, or placebo intervention not related to weight
control for comparison with (b).
• No improved access to water, or placebo intervention not
related to weight control for comparison with (c).
We will include trials that have additional concomitant interven-
tions that are the same in both the intervention and comparator
groups.
If multiple arms are included in a trial, the arms that meet the
inclusion criteria will be included in the review.
Minimum duration of intervention
We will define trial duration according to the number of weeks/
months over which the interventions have been conducted and
will only include trials in the analyses with interventions that last
for four weeks or more.
Specific exclusion criteria
• Trials of increased fluids for other conditions or indications
such as preventing urinary tract infections, or bladder cancer.
• Trials where water or other non-caloric beverages are
directly substituted for or compared with caloric beverages.
• Trials where non-caloric beverages are compared with the
same volume of water (as control).
Types of outcome measures
We will not exclude trials in the case that one or more of our
primary or secondary outcome measures were not reported in the
publication. In the case that none of our primary or secondary
outcomes was reported, we will contact authors to find out if we
can obtain the missing data. Where no relevant outcome data




• Health-related quality of life.
• Adverse events.
Secondary outcomes





• Physical activity levels.
• Levels of hormones that affect appetite.
• Socioeconomic effects.
Method and timing of outcome measurement
• Weight: measured in kg or pounds and measured once
participants were randomised to intervention/comparator groups
at a minimum of at baseline, anytime during the trial and at end
of the trial. All follow-up recorded post intervention will be
reported.
• Health-related quality of life: evaluated by a validated
instrument such as the Patient-Reported Outcomes
Measurement Information System (PROMIS) and measured at a
minimum of baseline and end of the trial.
• Adverse events: such as water toxicity, frequency or
nocturnal micturition/incontinence and measured by event at
any time after participants were randomised to intervention/
comparator groups.
• Anthropometric measures other than weight: BMI,
standardised BMI z-score (in children), skin-fold thickness or
direct fat measurement, measured at a minimum of baseline and
end of trial. All follow-up shall be reported and no minimum
follow-up shall be imposed.
• All-cause mortality: defined as death and measured at any
time.
• Morbidity: such as heart disease, stroke, myocardial
infarction, diabetes, and measured at baseline, anytime during
and at end of trial.
• Caloric intake, defined as energy intake over time. All
follow-up shall be reported and no minimum follow-up shall be
imposed.
• Satiety, defined as rating on numeric or visual analog scale.
All follow-up shall be reported and no minimum follow-up shall
be imposed.
• Physical activity levels, defined as hours of exercise weekly.
All follow-up shall be reported and no minimum follow-up shall
be imposed.
• Levels of hormones that affect appetite, defined as ghrelin,
leptin, insulin, cholecystokinin (CCK), glucagon-like peptide 1
(GPL-1). All follow-up shall be reported and no minimum
follow-up shall be imposed.
• Socioeconomic effects: such as direct costs defined as
admission/readmission rates, average length of stay, visits to
general practitioner, accident/emergency visits; medication
consumption; indirect costs defined as resources lost due to
illness by the participant or their family member.
Summary of findings
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We will present a ’Summary of findings’ table reporting the fol-
lowing outcomes listed according to priority.
1. Weight.




6. Physical activity levels.
7. Socioeconomic effects.
Search methods for identification of studies
Electronic searches
We will search the following sources from the inception of each
database to the specified date, and will place no restrictions on the
language of publication.





• Science Citation Index.
• ClinicalTrials.gov (https://clinicaltrials.gov/).
• World Health Organization (WHO) International Clinical
Trials Registry Platform (ICTRP) Search Portal (http://
apps.who.int/trialsearch/).
We will continuously apply a MEDLINE email alert service to
identify newly published studies using the same search strategy
as described for MEDLINE. For details on search strategies see
Appendix 1. After supplying the final review draft for editorial ap-
proval, wewill perform a complete updated search on all databases.
Should we identify new studies for inclusion, we will evaluate
these, incorporate the findings into our review, and resubmit an-
other review draft (Beller 2013).
If we detect additional relevant key words during any electronic
or other searches, we will modify the electronic search strategies to
incorporate these terms, and document the changes to the search
strategy.
Searching other resources
We will try to identify other potentially-eligible trials or ancillary
publications by searching the reference lists of retrieved included
trials, systematic reviews, meta-analyses and health technology as-
sessment reports. We will also contact study authors of included
trials to identify any further studies that we may have missed.
Data collection and analysis
Selection of studies
Two review authors (AP, AB) will independently scan the abstract,
title, or both, of every record retrieved, to determine which studies
we should assess further.We will investigate the full text articles of
all potentially-relevant articles. We will resolve any discrepancies
through consensus or recourse to the third review author (JC). If
we cannot resolve a disagreement, we will categorise the study as
a ’study awaiting classification’ and we will contact trial authors
for clarification. We will present an adapted Preferred Reporting
Items for Systematic Reviews and Meta-Analyses (PRISMA) flow
diagram to show the process of trial selection (Liberati 2009)
Data extraction and management
For trials that fulfil inclusion criteria, two review authors (AP, AB)
will independently extract key participant and intervention char-
acteristics. We will report data on efficacy outcomes and adverse
events using standard data extraction templates supplied by the
Cochrane Metabolic and Endocrine Disorders (CMED) Group.
We will resolve any disagreements by discussion, or, if required,
by consulting a third review author.
We will provide information (including trial identifier) about po-
tentially-relevant ongoing studies in the ’Characteristics of ongo-
ing studies’ table and in a joint appendix. We will try to find the
protocol for each included trial and will report primary, secondary,
and other outcomes in comparison with data in publications in a
joint appendix ’Matrix of study endpoints (publications and trial
documents)’.
We will email all authors of included trials to enquire whether
they would be willing to answer questions regarding their trials.
We will present the results of this survey in an appendix. We will
thereafter seek relevant missing information on the trial from the
primary author(s) of the article, if required.
Dealing with duplicate and companion publications
In the event of duplicate publications, companion documents or
multiple reports of a primary trial, we will maximise the infor-
mation yield by collating all available data and will use the most
complete dataset aggregated across all known publications. We
will list duplicate publications, companion documents, multiple
reports of a primary trial and trial documents of included trials
(such as trial registry information) as secondary references under
the study ID of the included trial. Furthermore, we will also list
duplicate publications, companion documents, multiple reports
of a trial and trial documents of excluded trials (such as trial reg-
istry information) as secondary references under the study ID of
the excluded trial.
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Data from clinical trial registers
In the case that data of included trials are available as study re-
sults in clinical trial registers such as ClinicalTrials.gov or similar
sources, we will make full use of this information and extract data.
If there is also a full publication of the trial, we will collate and
critically appraise all available data. If an included trial is marked
as a completed study in a clinical trial register but no additional
information (study results, publication or both) is available, we
will add this trial to the table ’Characteristics of studies awaiting
classification’.
Assessment of risk of bias in included studies
Two review authors (AP, AB) will independently assess the risk of
bias of each included study. We will resolve any disagreements by
consensus, or by consultation with a third review author (JC).
We will use the Cochrane ’Risk of bias’ assessment tool (Higgins
2011a; Higgins 2011b) and will judge ’Risk of bias’ criteria as
either ’low’, ’high’, or ’unclear’ risk and will evaluate individual
bias items as described in the Cochrane Handbook for Systematic
Reviews of Interventions (Higgins 2011a) where any of the specified
criteria for a judgement of ’low’, unclear’ or ’high’ risk of bias
justifies the associated categorisation.
Random sequence generation (selection bias due to
inadequate generation of a randomised sequence) -
assessment at trial level
We will describe for each included trial the method used to gen-
erate the allocation sequence in sufficient detail to allow an assess-
ment of whether it should produce comparable groups.
• Low risk of bias: sequence generation was achieved using
computer random number generation or a random number
table. Drawing of lots, tossing a coin, shuffling cards or
envelopes, and throwing dice are adequate if performed by an
independent person not otherwise involved in the trial. Use of
the minimisation technique will be considered as equivalent to
being random.
• Unclear risk of bias: insufficient information about the
sequence generation process.
• High risk of bias: the sequence generation method was non-
random (e.g. sequence generated by odd or even date of birth;
sequence generated by some rule based on date (or day) of
admission; sequence generated by some rule based on hospital or
clinic record number; allocation by judgement of the clinician;
allocation by preference of the participant; allocation based on
the results of a laboratory test or a series of tests; allocation by
availability of the intervention).
Allocation concealment (selection bias due to inadequate
concealment of allocations prior to assignment) - assessment
at trial level
We will describe for each included trial the method used to con-
ceal allocation to interventions prior to assignment and will assess
whether intervention allocation could have been foreseen in ad-
vance of, or during recruitment, or changed after assignment.
• Low risk of bias: central allocation (including telephone,
interactive voice-recorder, web-based and pharmacy-controlled
randomisation); sequentially-numbered drug containers of
identical appearance; sequentially-numbered, opaque, sealed
envelopes.
• Unclear risk of bias: insufficient information about the
allocation concealment.
• High risk of bias: using an open random allocation schedule
(e.g. a list of random numbers); assignment envelopes were used
without appropriate safeguards; alternation or rotation; date of
birth; case record number; any other explicitly unconcealed
procedure.
We will also evaluate trial baseline data to incorporate assessment
of baseline imbalance into the ’Risk of bias’ judgement for selection
bias (Corbett 2014). Chance imbalances might also affect judge-
ments on the risk of attrition bias. In case of unadjusted analyses
we will distinguish between studies rated as at low risk of bias on
the basis of both randomisation methods and baseline similarity,
and studies rated as at low risk of bias on the basis of baseline
similarity alone (Corbett 2014). We will re-classify judgements of
unclear, low or high risk of selection bias as specified in Appendix
2.
Blinding of participants and study personnel (performance
bias due to knowledge of the allocated interventions by
participants and personnel during the trial) - assessment at
outcome level
We will evaluate the risk of detection bias separately for each out-
come (Hróbjartsson 2013). We will note whether endpoints were
self-reported, investigator-assessed or adjudicated outcome mea-
sures (see below).
• Low risk of bias: blinding of participants and key study
personnel ensured, and unlikely that the blinding could have
been broken; no blinding or incomplete blinding, but the review
authors judge that the outcome is not likely to be influenced by
lack of blinding.
• Unclear risk of bias: insufficient information about the
blinding of participants and study personnel; the trial did not
address this outcome.
• High risk of bias: no blinding or incomplete blinding, and
the outcome is likely to be influenced by lack of blinding;
blinding of trial participants and key personnel attempted, but
likely that the blinding could have been broken, and the
outcome is likely to be influenced by lack of blinding.
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Blinding of outcome assessment (detection bias due to
knowledge of the allocated interventions by outcome
assessment) - assessment at outcome level
We will evaluate the risk of detection bias separately for each out-
come (Hróbjartsson 2013). We will note whether endpoints were
self-reported, investigator-assessed or adjudicated outcome mea-
sures (see below).
• Low risk of bias: blinding of outcome assessment ensured,
and unlikely that the blinding could have been broken; no
blinding of outcome assessment, but the review authors judge
that the outcome measurement is not likely to be influenced by
lack of blinding.
• Unclear risk of bias: insufficient information about the
blinding of outcome assessors; the trial did not address this
outcome.
• High risk of bias: no blinding of outcome assessment, and
the outcome measurement is likely to be influenced by lack of
blinding; blinding of outcome assessment, but likely that the
blinding could have been broken, and the outcome measurement
is likely to be influenced by lack of blinding.
Incomplete outcome data (attrition bias due to amount,
nature or handling of incomplete outcome data) - assessment
at outcome level
We will describe for each included trial, and for each outcome,
the completeness of data including attrition and exclusions from
the analysis. We will state whether attrition and exclusions were
reported and the number included in the analysis at each stage
(compared with the number of randomised participants per inter-
vention/comparator groups), if reasons for attrition or exclusion
where reported, and whether missing data were balanced across
groups or were related to outcomes. We will consider the implica-
tions of missing outcome data per outcome such as high drop-out
rates (e.g. above 15%) or disparate attrition rates (e.g. difference
of 10% or more between trial arms).
• Low risk of bias: no missing outcome data; reasons for
missing outcome data unlikely to be related to true outcome (for
survival data, censoring unlikely to be introducing bias); missing
outcome data balanced in numbers across intervention groups,
with similar reasons for missing data across groups; for
dichotomous outcome data, the proportion of missing outcomes
compared with observed event risk not enough to have a
clinically-relevant impact on the intervention effect estimate; for
continuous outcome data, plausible effect size (difference in
means or standardised difference in means) among missing
outcomes not enough to have a clinically-relevant impact on
observed effect size; appropriate methods, such as multiple
imputation, were used to handle missing data.
• Unclear risk of bias: insufficient information to assess
whether missing data in combination with the method used to
handle missing data were likely to induce bias; the trial did not
address this outcome.
• High risk of bias: reason for missing outcome data likely to
be related to true outcome, with either imbalance in numbers or
reasons for missing data across intervention groups; for
dichotomous outcome data, the proportion of missing outcomes
compared with observed event risk enough to induce clinically-
relevant bias in intervention effect estimate; for continuous
outcome data, plausible effect size (difference in means or
standardised difference in means) among missing outcomes
enough to induce clinically-relevant bias in observed effect size;
‘as-treated’ or similar analysis done with substantial departure of
the intervention received from that assigned at randomisation;
potentially inappropriate application of simple imputation.
Selective reporting (reporting bias due to selective outcome
reporting) - assessment at trial level
We will assess outcome reporting bias by integrating the results
of the appendix ’Matrix of trial endpoints (publications and trial
documents)’ (Boutron 2014; Jones 2015; Mathieu 2009), with
those of the appendix ”High risk of outcome reporting bias ac-
cording to ORBIT classification’ (Kirkham 2010). This analysis
will form the basis for the judgement of selective reporting.
• Low risk of bias: the trial protocol is available and all of the
trial’s pre-specified (primary and secondary) outcomes that are of
interest in the review have been reported in the pre-specified
way; the study protocol is not available but it is clear that the
published reports include all expected outcomes (ORBIT
classification).
• Unclear risk of bias: insufficient information about selective
reporting.
• High risk of bias: not all of the trial’s pre-specified primary
outcomes have been reported; one or more primary outcomes is
reported using measurements, analysis methods or subsets of the
data (e.g. sub-scales) that were not pre-specified; one or more
reported primary outcomes were not pre-specified (unless clear
justification for their reporting is provided, such as an
unexpected adverse effect); one or more outcomes of interest in
the review are reported incompletely so that they cannot be
entered in a meta-analysis; the trial report fails to include results
for a key outcome that would be expected to have been reported
for such a trial (ORBIT classification).
Other bias (bias due to problems not covered elsewhere) -
assessment at trial level
• Low risk of bias: the trial appeared to be free of other
sources of bias.
• Unclear risk of bias: insufficient information to assess
whether an important risk of bias existed; insufficient rationale
or evidence that an identified problem introduced bias.
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• High risk of bias: had a potential source of bias related to
the specific trial design used; has been claimed to have been
fraudulent; had some other serious problem.
We will present a ’Risk of bias’ graph and a ’Risk of bias’ summary
figure.
We will distinguish between self-reported, investigator-assessed
and adjudicated outcomemeasures.Wewill report whether weight
and caloric intake were investigator-assessed or patient-reported.
We define the following outcomes as self-reported.
• Weight as reported by participants.
• Anthropometric measures others than weight, as measured
by participants.
• Adverse events as reported by participants.
• Satiety as reported by participants.
• Physical activity levels as reported by participants.
• Health-related quality of life.
We define the following outcomes as investigator-assessed.
• Anthropometric measures others than weight, as measured
by investigators
• Adverse events as reported by investigators.




Summary assessment of risk of bias
Risk of bias for a trial across outcomes: some ’Risk of bias’
domains like selection bias (sequence generation and allocation
sequence concealment) affect the risk of bias across all outcome
measures in a trial. In case of high risk of selection bias, all end-
points investigated in the associated trial will be marked as ’high’
risk. Otherwise, we will not perform a summary assessment of the
risk of bias across all outcomes for a trial.
Risk of bias for an outcome within a trial and across domains:
we will assess the risk of bias for an outcome measure including all
of the entries relevant to that outcome, i.e. both trial-level entries
and outcome-specific entries. ’Low’ risk of bias is defined as low
risk of bias for all key domains, ’unclear’ risk of bias as unclear risk
of bias for one or more key domains and ’high’ risk of bias as high
risk of bias for one or more key domains.
Risk of bias for an outcome across trials and across domains:
these are our main summary assessments that will be incorporated
in our judgements about the quality of evidence in the ’Summary
of findings’ tables. ’Low’ risk of bias is defined as most information
coming from trials at low risk of bias, ’unclear’ risk of bias as most
information coming from trials at low or unclear risk of bias and
’high’ risk of bias as a sufficient proportion of information coming
from trials at high risk of bias.
Measures of treatment effect
We will express dichotomous data as odds ratios (ORs) or risk
ratios (RRs) with 95% confidence intervals (CIs). We will ex-
press continuous data as mean differences (MDs) with 95% CIs.
For continuous outcomes measuring the same underlying concept
(e.g. health-related quality of life) but using differentmeasurement
scales, we will calculate the standardised mean difference (SMD).
We will express time-to-event data as hazard ratios (HRs) with
95% CIs.
Unit of analysis issues
We will take into account the level at which randomisation oc-
curred, such as cross-over trials, cluster-randomised trials andmul-
tiple observations for the same outcome. If more than one com-
parison from the same trial is eligible for inclusion in the same
meta-analysis, we will either combine groups to create a single
pair-wise comparison or appropriately reduce the sample size so
that the same participants do not contributemultiply (splitting the
’shared’ group into two or more groups). While the latter approach
offers some solution to adjusting the precision of the comparison,
it does not account for correlation arising from the same set of
participants being in multiple comparisons (Higgins 2011a).
We will attempt to reanalyse cluster randomised trials that have
not appropriately adjusted for potential clustering of participants
within clusters in their analysis. The variance of the intervention
effects will be inflated by a design effect (DEFF). Calculation of
a DEFF involves estimation of an intra-cluster correlation (ICC).
Estimates of ICCs will be obtained through contact with authors,
or imputed using estimates fromother included studies that report
ICCs, or using external estimates from empirical research (e.g.
Bell 2013). We plan to examine the impact of clustering using
sensitivity analyses.
Dealing with missing data
If possible, we will obtain missing data from trial authors and will
carefully evaluate important numerical data such as screened, ran-
domly-assigned participants as well as intention-to-treat (ITT),
and as-treated and per-protocol populations. We will investigate
attrition rates (e.g. drop-outs, losses to follow-up, withdrawals),
and we will critically appraise issues concerning missing data
and imputation methods (e.g. last observation carried forward
(LOCF)).
In trials where the standard deviation (SD) of the outcome is not
available at follow-up, or cannot be recreated, we will standardise
by the average of the pooled baseline SD from those trials in which
this information was reported.
Where means and SDs for outcomes have not been reported and
we have not received the needed information from trial authors,
we will impute these values by estimating the mean and variance
from the median, range, and the size of the sample (Hozo 2005).
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We will investigate the impact of imputation on meta-analyses
by performing sensitivity analyses and report per outcome which
trials were included with imputed SDs.
Assessment of heterogeneity
In the event of substantial clinical or methodological heterogene-
ity, we will not report trial results as the pooled effect estimate in
a meta-analysis.
We will identify heterogeneity (inconsistency) through visual in-
spection of the forest plots and by using a standard Chi² test with
a significance level of α = 0.1. In view of the low power of this
test, we will also consider the I² statistic, which quantifies incon-
sistency across studies, to assess the impact of heterogeneity on the
meta-analysis (Higgins 2002; Higgins 2003), where an I² statis-
tic of 75% or more indicates a considerable level of heterogeneity
(Higgins 2011a).
When we find heterogeneity, we will attempt to determine possi-
ble reasons for it by examining individual trial and subgroup char-
acteristics.
Assessment of reporting biases
If we include 10 or more trials investigating a particular outcome,
we will use funnel plots to assess small-trial effects. Several expla-
nations may account for funnel plot asymmetry, including true
heterogeneity of effect with respect to trial size, poor methodolog-
ical design (and hence bias of small trials) and publication bias.
Therefore we will interpret results carefully (Sterne 2011).
Data synthesis
Unless good evidence shows homogeneous effects across trials, we
will primarily summarise low risk of bias data using a random-ef-
fects model (Wood 2008). We will interpret random-effects meta-
analyses with due consideration to the whole distribution of ef-
fects, ideally by presenting a prediction interval (Higgins 2009).
A prediction interval specifies a predicted range for the true treat-
ment effect in an individual trial (Riley 2011). For rare events such
as event rates below 1% we will use Peto’s odds ratio method, pro-
vided that there is no substantial imbalance between intervention
and comparator group sizes and intervention effects are not excep-
tionally large. In addition, we will also perform statistical analyses
according to the statistical guidelines contained in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011a).
Quality of evidence
Wewill present the overall quality of the evidence for each outcome
specified under ’Types of outcome measures: Summary of finding’
according to the Grading of Recommendations Assessment, De-
velopment and Evaluation (GRADE) approach, which takes into
account issues related not only to internal validity (risk of bias,
inconsistency, imprecision, publication bias) but also to external
validity, such as directness of results. Two review authors (AP, AB)
will independently rate the quality of evidence for each outcome.
We will present a summary of the evidence in a ’Summary of find-
ings’ table. This will provide key information about the best esti-
mate of the magnitude of the effect, in relative terms and as abso-
lute differences, for each relevant comparison of alternative man-
agement strategies, numbers of participants and trials addressing
each important outcome and rating of overall confidence in effect
estimates for each outcome. We will create the ’Summary of find-
ings’ table based on the methods described in the Cochrane Hand-
book for Systematic Reviews of Interventions by means of Review
Manager (RevMan)’s table editor (RevMan 2014).Wewill include
an appendix titled ’Checklist to aid consistency and reproducibil-
ity of GRADE assessments’ (Meader 2014) to help with standard-
isation of the ’Summary of findings’ tables (Higgins 2011a). Al-
ternatively, we will use the GRADEpro Guideline Development
Tool (GDT) software (GRADEproGDT 2015) and present evi-
dence profile tables as an appendix. We will present results for the
outcomes as described in the Types of outcome measures section.
If meta-analysis is not possible, we will present the results in a nar-
rative format in the ’Summary of findings’ table. We will justify
all decisions to downgrade the quality of studies using footnotes,
and we will make comments to aid the reader’s understanding of
the Cochrane review where necessary.
Subgroup analysis and investigation of heterogeneity
We expect the following characteristics to introduce clinical het-
erogeneity, and we plan to carry out the following subgroup anal-
yses including investigation of interactions.
• Type of non-caloric beverage consumed (e.g. water, green
tea) versus all other non-caloric beverages.
• Volume consumed.
• Effect in people of different levels of adiposity (normal,
overweight, obese).
• Effect in different age groups (children, adults, elderly).
• Effect of timing of consumption (pre-load before meals or
before different meals versus any time).
• Effects of concomitant dietary (e.g. hypo-caloric diet) or
physical activity changes.
Sensitivity analysis
We plan to perform sensitivity analyses to explore the influence of
the following factors (when applicable) on effect sizes, by restrict-
ing the analysis to the following.
• Published studies.
• Taking into account risk of bias, as specified in the
Assessment of risk of bias in included studies section.
• Very long or large trials to establish the extent to which they
dominate the results.
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• Trials using the following filters: diagnostic criteria,
imputation, language of publication, source of funding (industry
versus other), or country.
We will also test the robustness of the results by repeating the anal-
ysis using different measures of effect size (RR, OR etc.) and dif-
ferent statistical models (fixed-effect and random-effects models).
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A P P E N D I C E S
Appendix 1. Search strategies
Cochrane Library
#1 MeSH descriptor: [Overweight] this term only
#2 MeSH descriptor: [Obesity] this term only
#3 MeSH descriptor: [Obesity, Morbid] explode all trees
#4 MeSH descriptor: [Obesity, Abdominal] explode all trees
#5 MeSH descriptor: [Body Mass Index] explode all trees
#6 MeSH descriptor: [Energy Intake] this term only
#7 MeSH descriptor: [Eating] this term only
#8 MeSH descriptor: [Hunger] this term only
#9 MeSH descriptor: [Satiation] explode all trees
#10 MeSH descriptor: [Thermogenesis] this term only
#11 (weight next (gain or loss or lose or losing or maintain* or maintenance or change* or manage* or control* or reduc*)):ti,ab,kw
(Word variations have been searched)
#12 bmi or “body mass index”:ti,ab,kw (Word variations have been searched)
#13 obes*:ti,ab,kw (Word variations have been searched)
#14 overweight or “over weight” or overeat* or “over eat*”:ti,ab,kw (Word variations have been searched)
#15 food intake or “energy intake”:ti,ab,kw (Word variations have been searched)
#16 eating:ti,ab,kw (Word variations have been searched)
#17 hunger:ti,ab,kw (Word variations have been searched)
#18 satiety or satiation:ti,ab,kw (Word variations have been searched)
#19 fullness:ti,ab,kw (Word variations have been searched)
#20 thermogenesis:ti,ab,kw (Word variations have been searched)
#21 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #
20
#22 MeSH descriptor: [Beverages] this term only
#23 MeSH descriptor: [Mineral Waters] explode all trees
#24 MeSH descriptor: [Drinking Water] explode all trees
#25 MeSH descriptor: [Tea] explode all trees
#26 MeSH descriptor: [Teas, Herbal] explode all trees
#27 water near/5 (drink* or consumption or consume*):ti,ab,kw (Word variations have been searched)
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(Continued)
#28 beverage* or tea or teas:ti,ab,kw (Word variations have been searched)
#29 #22 or #23 or #24 or #25 or #26 or #27 or #28
#30 #21 and #29
MEDLINE OvidSP
1 overweight/ or obesity/ or obesity, morbid/ or Obesity, Abdominal/





7 (weight adj (gain or loss or lose or losing or maintain* or maintenance or change* or manage* or control* or reduc*)).tw
8 obes*.ti,ab.
9 (overweight or over weight or overeat* or over eat*).tw.
10 (bmi or body mass index).tw.
11 (food intake or energy intake).tw.
12 hunger.tw.
13 (satiety or satiation).tw.
14 fullness.tw.
15 thermogenesis.tw.
16 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15
17 beverages/ or exp drinking water/ or mineral waters/ or exp tea/ or teas, herbal/ or teas, medicinal/
18 (water adj5 (drink* or consumption or consume*)).tw.
19 (beverage* or tea or teas).tw.
20 17 or 18 or 19
21 16 and 20
22 randomized controlled trial.pt.







30 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29
31 exp animals/ not humans.sh.
32 30 not 31
33 21 and 32
EMBASE OvidSP
1 abdominal obesity/ or obesity/ or morbid obesity/
2 weight reduction/
3 food intake/ or eating/




8 (weight adj (gain or loss or lose or losing or maintain* or maintenance or change* or manage* or control* or reduc*)).tw
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(Continued)
9 obes*.ti,ab.
10 (overweight or over weight or overeat* or over eat*).tw.
11 (bmi or body mass index).tw.
12 (food intake or energy intake).tw.
13 hunger.tw.
14 (satiety or satiation).tw.
15 fullness.tw.
16 thermogenesis.tw.
17 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16
18 beverage/ or carbonated water/ or drinking water/ or herbal tea/ or mineral water/ or tea/
19 (water adj5 (drink* or consumption or consume*)).tw.
20 (beverage* or tea or teas).tw.
21 18 or 19 or 20
22 17 and 21
23 limit 22 to “therapy (maximizes sensitivity)”
24 (exp animals/ or nonhuman/) not human/
25 23 not 24
CINAHL (EBSCO Host)
1 (MH “Obesity”) OR (MH “Obesity, Morbid”)
2 (MH “Weight Loss”)
3 (MH “Body Mass Index”)




8 TI ( (weight N1 (gain or loss or lose or losing or maintain* or maintenance or change* or manage* or control* or reduc*)) ) OR
AB ( (weight N1 (gain or loss or lose or losing or maintain* or maintenance or change* or manage* or control* or reduc*)) )
9 TI obes* OR AB obes*
10 TI ( overweight OR “over weight” OR overeat* OR “over eat*” ) OR AB ( overweight OR “over weight” OR overeat* OR “over
eat*” )
11 TI ( bmi OR “body mass index” ) OR AB ( bmi OR “body mass index” )
12 TI ( “food intake” OR “energy intake” ) OR AB ( “food intake” OR “energy intake” )
13 TI hunger OR AB hunger
14 TI ( satiety OR satiation ) OR AB ( satiety OR satiation )
15 TI fullness OR AB fullness
16 TI thermogenesis OR AB thermogenesis
17 S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7 OR S8 OR S9 OR S10 OR S11 OR S12 OR S13 OR S14 OR S15 OR S16
18 (MH “Tea+”) OR (MH “Water+”) OR (MH “Beverages”)
19 TI ( water N5 (drink* OR consumption OR consume*) ) OR AB ( water N5 (drink* OR consumption OR consume*) )
20 TI ( beverage* OR tea OR teas ) OR AB ( beverage* OR tea OR teas )
21 S18 OR S19 OR S20
22 S17 AND S21
23 S17 AND S21 Limiters - Clinical Queries: Therapy - High Sensitivity
Science Citation Index
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(Continued)
1. TS=(bmi or “body mass index”) OR TS=(“food intake” or “energy intake”) OR TS=(obes* OR overweight OR overeat* OR
“over eat*”) OR TS=(“weight gain” OR “weight loss” OR “weight maintenance” or “weight change*” OR “weight management”
OR “weight reduction” OR “weight control”) OR TS=(thermogenesis) OR TS=(hunger or satiety or satiation or fullness) OR TS=
(eating)
2. TS=(beverage* OR tea OR teas) OR TS=((water NEAR/5 (drink* OR consume* OR consumption)))
3. TS=(random* or blind* or allocat* or assign* or trial* or placebo* or crossover* or cross-over*)
#3 AND #2 AND #1
ClinicalTrials.gov (Advanced search)
Search Terms: overweight OR obesity OR obese OR “weight control” OR “weight reduction” OR “weight loss” OR “weight
maintenance” OR “weight management” OR “weight change” OR “weight changes” OR “body mass index”
Study Type: Interventional Studies
Interventions: water OR tea OR beverage OR beverages
WHO ICTRP Search Portal (Standard search)
(to be run as one search string)
overweight AND water OR
overweight AND tea OR
overweight AND beverage* OR
obes* AND water OR
obes* AND tea OR
obes* AND beverage* OR
weight AND water OR

















Number (no) records retrieved:
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EbscoHOST Clinical Queries: Therapy - High Sensitivity
Wong 2006a
EMBASE RCTs
Ovid Clinical Queries: Treatment (2 or more terms high sensitivity)
Wong 2006b
MEDLINE RCTs
Cochrane Highly Sensitive Search Strategy for identifying randomized trials in MEDLINE: sensitivity-
maximizing version (2011 revision); Ovid format
Lefebvre 2011
Appendix 2. Selection bias decisions
Selection bias decisions for trials reporting unadjusted analyses: comparison of results obtained using method details alone








Ris of bias using baseline in-
formation and methods re-
porting




Groups appear similar at base-
line for all important prognos-
tic variables
Low risk
Limited or no baseline details Unclear risk
Would generate a truly random
sample, with robust allocation
concealment




Groups appear similar at base-
line for all important prognos-
tic variables
Low risk
Limited baseline details, show-
ing balance in some important
prognostic variablesb
Low risk
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(Continued)
No baseline details Unclear risk
Sequence is not truly ran-
domised, or allocation conceal-
ment is inadequate




Groups appear similar at base-
line for all important prognos-
tic variables
Low risk
Limited baseline details, show-
ing balance in some important
prognostic variablesb
Unclear risk
No baseline details High risk
aTaken from Corbett 2014; judgements highlighted in grey indicate situations in which the addition of baseline assessments would
change the judgement about risk of selection bias, compared with using methods reporting alone.
bDetails for the remaining important prognostic variables are not reported.
cImbalance identified that appears likely to be due to chance
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N O T E S
We have based parts of the Methods and Appendix 1 sections of this Cochrane protocol on a standard template established by the
CMED Group.
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